12:00 AM
Jul 15, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Yondelis trabectedin regulatory update

PharmaMar said Johnson & Johnson's Janssen Products L.P. unit received approval for Yondelis trabectedin in the United Arab Emirates, South Africa, Guatemala and Croatia for 2 indications - to treat relapsed platinum-sensitive ovarian cancer in combination with Caelyx pegylated liposomal...

Read the full 190 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >